BGB-3111_BGB-A317_Study_001
Completed
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
BeOne Study ID 
BGB-3111_BGB-A317_Study_001
ClinicalTrials.gov ID
Study Overview
Sex:
All
Age: 18 Years / N/A
Study Documents
Study Protocol Statistical Analysis PlanStudy Overview
Sex:
All
Age: 18 Years / N/A